Last reviewed · How we verify
Patidegib Topical Gel
Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors.
Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors. Used for Basal cell carcinoma (topical treatment), Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
At a glance
| Generic name | Patidegib Topical Gel |
|---|---|
| Also known as | Patidegib, IPI-926, Saridegib, SGT-610 |
| Sponsor | Sol-Gel Technologies, Ltd. |
| Drug class | Smoothened (SMO) inhibitor |
| Target | Smoothened (SMO) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Patidegib inhibits smoothened, a key component of the hedgehog signaling pathway that is aberrantly activated in basal cell carcinoma and other skin cancers. By blocking this pathway, the drug suppresses tumor cell growth and proliferation. As a topical gel formulation, it delivers the active agent directly to affected skin lesions while minimizing systemic exposure.
Approved indications
- Basal cell carcinoma (topical treatment)
- Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
Common side effects
- Application site reactions (erythema, irritation)
- Dermatitis
- Pruritus
Key clinical trials
- Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (PHASE3)
- Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) (PHASE3)
- Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) (PHASE3)
- An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC (PHASE2)
- Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients (PHASE2)
- Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Patidegib Topical Gel CI brief — competitive landscape report
- Patidegib Topical Gel updates RSS · CI watch RSS
- Sol-Gel Technologies, Ltd. portfolio CI